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Background. Anal cancer is one of the most common cancers affecting individuals infected with human
immunodeficiency virus (HIV), although few have evaluated rates separately for men who have sex with men
(MSM), other men, and women. There are also conflicting data regarding calendar trends.
Methods. In a study involving 13 cohorts from North America with follow-up between 1996 and 2007, we
compared anal cancer incidence rates among 34 189 HIV-infected (55% MSM, 19% other men, 26% women) and
114 260 HIV-uninfected individuals (90% men).
Results. Among men, the unadjusted anal cancer incidence rates per 100 000 person-years were 131 for HIV-
infected MSM, 46 for other HIV-infected men, and 2 for HIV-uninfected men, corresponding to demographically
adjusted rate ratios (RRs) of 80.3 (95% confidence interval [CI], 42.7–151.1) for HIV-infected MSM and 26.7 (95%
CI, 11.5–61.7) for other HIV-infected men compared with HIV-uninfected men. HIV-infected women had an anal
cancer rate of 30/100 000 person-years, and no cases were observed for HIV-uninfected women. In a multivariable
Poisson regression model, among HIV-infected individuals, the risk was higher for MSM compared with other
men (RR, 3.3; 95% CI, 1.8–6.0), but no difference was observed comparing women with other men (RR, 1.0; 95%
CI, 0.5–2.2). In comparison with the period 2000–2003, HIV-infected individuals had an adjusted RR of 0.5 (95%
CI, .3–.9) in 1996–1999 and 0.9 (95% CI, .6–1.2) in 2004–2007.
Conclusions. Anal cancer rates were substantially higher for HIV-infected MSM, other men, and women
compared with HIV-uninfected individuals, suggesting a need for universal prevention efforts. Rates increased
after the early antiretroviral therapy era and then plateaued.
With the dramatic decline in human immunodeficiency
virus (HIV)-related mortality resulting from advances in
combination antiretroviral therapy (ART) and the
longer life expectancy and aging of HIV-infected
persons, there is growing concern about an increased
burden of certain cancers, particularly infection-related
cancers such as anal cancer. Meta-analyses have re-
ported that anal cancer incidence rates are 30 times as
high for HIV-infected individuals compared with the
general population [1, 2], although incidence rate es-
timates from individual studies have varied widely
from 18 to 149 cases per 100 000 person-years [3–10].
Understanding the factors that contribute to the
variability in anal cancer incidence rates in HIV-infected
persons is critical for targeting screening and prevention
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efforts to appropriate high-risk groups. In general, HIV-infected
men who have sex with men (MSM) have been observed to
have the highest rates [9, 11, 12]. HIV-infected heterosexual
men also have been reported to have higher rates than HIV-
infected women [12–14], although some studies have in-
dicated no differences by sex [2, 4]. Finally, it is unclear
how improvements in immune function and extension of
life with effective ART use have affected the incidence of anal
cancer in HIV-infected persons. In the current study, we have
used data from a multicohort collaboration in the United
States and Canada to assess key factors contributing to the
heterogeneity in anal cancer incidence.
METHODS
Participants and Data Sources
We analyzed data from 13 cohort studies (10 from the United
States and 3 from Canada) that are included in the North
American AIDS Cohort Collaboration on Research and Design
(NA-ACCORD) for the years 1996–2007. Cohorts were included
if they provided data on anal cancers and sexual orientation.
Study methods for NA-ACCORD have been described elsewhere
[15]. Study protocols were approved by the local institutional
review board for each cohort.
Eleven of the 13 participating cohorts were clinic-based, and
data were obtained from medical records. The remaining 2
participating cohorts (Multicenter AIDS Cohort Study [MACS],
and Women’s Interagency HIV Study [WIHS]) were interval-
based, and data were obtained as part of a research protocol at
scheduled 6-month study visits. All contributing cohorts
used standardized methods of data collection, and submitted
demographic, treatment, clinical, laboratory, and vital status
data on enrolled HIV-infected individuals. In addition, 3
cohorts (MACS, WIHS, and Kaiser Permanente Northern
California [KPNC]) contributed data on HIV-uninfected
individuals. Because sexual orientation was unknown for
the majority of HIV-uninfected individuals, we were unable
to stratify men in the comparison group by MSM status.
Incident anal cancer diagnoses were ascertained separately
by each cohort from medical records, patient interviews
(confirmed by medical record reviews), or linkage with a can-
cer registry. Cases comprised all anal cancer diagnoses, re-
gardless of histology, because histological information was not
provided by all cohorts. Individuals with prevalent anal cancer
were excluded.
Statistical Methods
The primary objective was to estimate anal cancer incidence
overall and over time among HIV-infected MSM, HIV-infected
other men (ie, heterosexual, injection drug use [IDU], or other
HIV risk factor), and HIV-infected women. We compared
incidence rates to the reference groups of HIV-uninfected men
and women. For each cohort member, the start of follow-up
(ie, baseline) was defined as the cohort entry date, or 1 January
1996, whichever came last. Individuals were followed until
there was an anal cancer diagnosis, loss to follow-up, death,
or up to 31 December 2007, whichever occurred first.
We initially computed anal cancer incidence rates over the
entire study period. Adjusted rate ratios (RRs) were calculated
for HIV-infected MSM and other men compared with HIV-
uninfected individuals (reference group) using Poisson
models with terms for calendar era (1996–1999, 2000–2003,
and 2004–2007), age at entry into a calendar era by 5-year age
groups, race/ethnicity (white, black, other), and cohort. Mul-
tiple imputation [16] was used to impute missing race/ethnicity
on the basis of an individual’s age, HIV status, calendar period
of entry into cohort, anal cancer status, and cohort. We also
computed anal cancer incidence rates for HIV-infected and
uninfected women, although adjusted RRs were not com-
puted because no cases were observed among HIV-uninfected
women.
We then computed cohort-specific anal cancer incidence
rates for HIV-infected individuals. Using linear regression, the
cohort-specific incidence rate was modeled as a function of
each cohort’s prevalence of MSM. Each of the 13 observations
representing an individual cohort was weighted according to
the amount of person-time contributed by that cohort. We
report the R2 as a measure of the amount of variability in
cohort-specific rates explained by the cohort-specific preva-
lence of MSM.
In subsequent analyses, we evaluated whether anal cancer
incidence rates have changed over time (1996–1999, 2000–2003,
and 2004–2007) for HIV-infected MSM, other men, and
women. Denominators for these rates were obtained by dividing
each subject’s person-time into the corresponding calendar eras;
to obtain numerators, anal cancer diagnoses made during
a given era were assigned to that era. P values comparing anal
cancer incidence rates by era (2000–2003 as reference) were
obtained from a Poisson regression model, and a global
P value was based on the likelihood ratio statistic. Multivar-
iable Poisson models were then used to evaluate changes in
RRs over time for HIV-infected MSM and other men com-
pared with HIV-uninfected men, adjusting for race/ethnicity,
age at entry into calendar era in 5-year groups, and cohort.
Because only 3 of the 13 cohorts contributed data on HIV-
uninfected individuals, we also report standardized incidence
ratios (SIRs) for HIV-infected MSM, other men, and women,
adjusting for age and race/ethnicity, using national US Sur-
veillance, Epidemiology and End Results (SEER) program rates
for 1996–2005 [17].
Finally, for HIV-infected individuals, we computed ad-
justed RRs in a multivariable Poisson model with terms for
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MSM/other men/women, calendar era, race/ethnicity, age at
entry into calendar era, baseline CD41 T-cell count, and cohort.
RESULTS
Thirteen NA-ACCORD cohorts contributed a total of 34 189
HIV-infected individuals (55%MSM, 19% other men, and 26%
women; Table 1). Three of these cohorts also contributed
114 260 HIV-uninfected individuals (90% men). Median age
by HIV infection status was similar among men and women.
Among those with known race/ethnicity, most HIV-infected
MSM and HIV-uninfected individuals were white, whereas
most HIV-infected other men and women were black. The
most common HIV transmission risk was heterosexual sex
for both HIV-infected other men (59%) and women (61%).
The anal cancer incidence rate per 100 000 person-years for
HIV-infected MSM, other men, and women was 131, 46, and
30, respectively (Table 1). The higher rate for HIV-infected
MSM compared with both other men and women was sta-
tistically significant (both P , .001); incidence rates for HIV-
infected other men and women did not significantly differ
(P 5 .27). Among HIV-uninfected men, there were 13 anal
cancer cases corresponding to an incidence rate of 2 cases per
100 000 person-years. With HIV-uninfected men as the refer-
ence group, adjusted RRs were 80.3 (95% CI, 42.7–151.1) for
HIV-infected MSM and 26.7 (95% CI, 11.5–61.7) for HIV-
infected other men. No anal cancer cases were observed among
HIV-uninfected women.
Figure 1 shows the anal cancer incidence rate per 100 000
person-years for each of 13 cohorts as a function of each
Table 1. Baseline Characteristics, Anal Cancer Rates, and Rate Ratios by HIV Status, Men Who Have Sex With Men, and Sex, North
American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), Years 1996–2007
HIV-Infected HIV-Uninfected
MSM Other Men Women Men Women
Baseline characteristics
No. 18 855a 6492a 8842 102 607 11 653
Median age (IQR) 38 (33–44) 40 (35–46) 36 (30–43) 40 (34–47) 37 (31–44)
Race/ethnicity
Black 3383 (18%) 3360 (52%) 4770 (54%) 6153 (6%) 1678 (14%)
White 11 951 (63%) 1773 (27%) 2051 (23%) 32 915 (32%) 4306 (37%)
Otherb 1946 (10%) 732 (11%) 1269 (14%) 19 631 (19%) 3201 (27%)
Unknown 1575 (8%) 627 (10%) 752 (9%) 43 908 (43%) 2468 (21%)
HIV risk group
MSM 18 855 (100%) 0 (0%) 0 (0%) . .
IDU 0 (0%) 2225 (34%) 1595 (18%) . .
Heterosexual 0 (0%) 3820 (59%) 5433 (61%) . .
Other 0 (0%) 447 (7%) 464 (5%) . .
Unknown 0 (0%) 0 (0%) 1355 (15%) . .
Median year start of
follow-up (IQR)
2000 (1997–2004) 2000 (1997–2003) 2000 (1996–2003) 1998 (1996–2003) 1998 (1996–2003)
Median baseline CD4
cells/lL (IQR)c
320 (140–505) 225 (65–418) 336 (155–538) . .
Anal cancer rates and rate ratios
Cases 122 14 15 13 0
Person-years 93 063 30 570 49 676 585 049 67 942
Median years follow-up (IQR) 4.0 (1.6–7.8) 3.9 (1.6–7.2) 5.3 (2.0–8.8) 4.7 (2.0–10.0) 5.0 (2.1–9.9)
Incidence rate per 100 000
person-years (95% CI)
131 (109–157) 46 (25–77) 30 (17–50) 2 (1–4) 0 (0–5)
Rate ratio (95% CI) 80.3 (42.7–151.1)d 26.7 (11.5–61.7)d Undefinede Reference Undefinede
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; IDU, injection drug use; IQR, interquartile range; MSM, men who have sex with men.
a Excludes 2280 HIV-infected men with missing or unknown HIV risk group.
b Other race/ethnicity category was predominantly Hispanic.
c Closest CD4 test result within 1 year of start of follow-up; 0.8% had missing baseline CD4.
d Rate ratios for HIV-infected MSM and other men compared with HIV-uninfected men from Poisson regression models adjusted for race/ethnicity, calendar era,
age at entry into calendar era, and cohort.
e Zero cases of anal cancer among the reference group of HIV-uninfected females.
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cohort’s MSM prevalence. The line represents the results of
the weighted linear regression model with an intercept of 28.3
cases per 100 000 person-years, and slope of 1.18 cases per
100 000 person years per 1% increase (P 5 .047) in cohort-
specific prevalence of MSM. Thus, the anticipated anal cancer
incidence rate for a population with 0% MSM would be
28 cases per 100 000 person-years (eg, 28.3 1 1.18 3 0 5 28.3),
whereas the incidence rate for a population with 100%
MSM would be 146 cases per 100 000 person-years (eg,
28.3 1 1.18 3 100 5 146.3). Overall, the R2 from the model
indicated that the cohort-specific prevalence of MSM ex-
plained 31% of the variability in incidence rates. Excluding
the outlier cohort with a very high anal cancer incidence
rate had little effect on results (data not shown) because the
cohort contributed ,0.5% of all HIV-infected person-time.
Figure 2 shows the change in crude incidence rates over time
for HIV-infected MSM, other men, and women. For MSM, the
increase in rate between 1996–1999 and 2000–2003 was sig-
nificant (P 5 .03), whereas the difference in rates between
2000–2003 and 2004–2007 was not (P 5 .33). The pattern
observed was similar for other men and women such that the
incidence rate was lowest in the earliest era (1996–1999), al-
though differences between eras were not significant. At each
time point, the incidence rate for MSM was higher than for
other men or women. The incidence rate was similar for other
men and women at each time point, with substantial overlap of
confidence intervals.
Table 2 presents calendar era–specific, adjusted RRs for anal
cancer for HIV-infected MSM and HIV-infected other men
compared with HIV-uninfected men (reference). For HIV-in-
fected MSM, the incidence rate compared with HIV-uninfected
men was lowest in 1996–1999 with an adjusted RR of 60.8.
The RR increased for HIV-infected MSM during 2000–2003
(P 5 .06) but did not continue to increase during 2004–2007
(P 5 .22). For HIV-infected other men, the incidence rate
compared with HIV-uninfected men was also lowest in 1996–
1999 with an adjusted RR of 18.2. Although slight increases in
the RR were observed over time, differences between eras were
not significant. SIRs for the same comparisons were of similar
magnitude across time periods for HIV-infected MSM and
other men (Table 2). Additionally, SIRs indicated a similar
pattern for HIV-infected women with an increase in the SIR
from 0 in 1996–1999 to 41.5 in 2000–2003 but a reduced SIR
of 24.7 in 2004–2007.
Multivariable analysis of risk factors for anal cancer among
HIV-infected individuals (Table 3) indicated that MSM were
associated with a significantly greater incidence rate (RR, 3.3;
95% CI, 1.8–6.0) compared with HIV-infected other men,
whereas no difference was found comparing women and other
men (RR, 1.0; 95% CI, .5–2.2). The incidence rate during
1996–1999 was significantly lower than the incidence rate in
2000–2003 (RR, 0.5; 95% CI, .3–.9), but the incidence rate did
not significantly change between 2000–2003 and 2004–2007.
Other factors significantly associated with incident anal can-
cer included race/ethnicity (RR, 0.3; 95% CI, .1–.7 for other
race/ethnicities compared with whites), age (RR per 10-year
increase in age, 1.3; 95% CI, 1.1–1.5), and baseline CD4 count
(RR, 0.2; 95% CI, .1–.3 for CD4 $500 compared with CD4
,200).
DISCUSSION
In this large multicohort study, we confirmed that HIV-infected
MSM experienced the greatest risk for anal cancer with in-
cidence rates.80 times as high as HIV-uninfected individuals.
Incidence rates differed widely across the 13 individual co-
horts, with a large amount (31%) of the variation accounted
for by the cohort-specific prevalence of MSM. We also found
that both HIV-infected other men and women had sub-
stantially higher rates than HIV-uninfected men and women,
and that HIV-infected other men and women had similar
rates. Finally, we observed that rates of anal cancer for HIV-
infected individuals increased after the early ART era and then
plateaued in more recent years.
Figure 1. Cohort-specific anal cancer incidence rates by cohort-specific
prevalence of men who have sex with men (MSM), North American
AIDS Cohort Collaboration on Research and Design (NA-ACCORD), years
1996–2007. Each point represents 1 of 13 cohorts contributing data. The
line represents the results of the weighted linear regression model
with an intercept of 28.3 cases per 100 000 person-years, and slope of
1.18 cases per 100 000 person years per 1% increase in cohort-specific
prevalence of MSM.
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The substantially higher incidence rate of anal cancer
among HIV-infected MSM was observed initially in the pre-
ART era [18] and since has been confirmed by some studies
[12, 19] but not others [4]. The French Hospital Database
study indicated that HIV-infected MSM had an 8 times as high
incidence rate of anal cancer compared with HIV-infected
women [12], which is comparable to our finding of a 4 times
as high rate comparing these same groups. Chaturvedi et al
[19] reported that MSM had an SIR of 52, the highest of all
risk groups examined. Finally, Dal Maso et al [4] reported that
among Italians with AIDS, those with a history of IDU had
the highest SIR (SIR, 85), followed by MSM (SIR, 47) and
heterosexuals (SIR, 10).
We also observed that HIV-infected other men and women
had similar anal cancer incidence, although both had elevated
incidence rates compared with HIV-uninfected individuals.
Piketty et al [12] reported a higher incidence of anal cancer for
both HIV-infected MSM and other men compared with HIV-
infected women. Chaturvedi et al [19], on the other hand,
reported similar SIRs for heterosexual men (SIR, 14) and
women (SIR, 15). Others have compared incidence rates by
sex (ie, grouping MSM and other men together), with some
indicating a higher incidence for anal cancer among men
[13, 14], and others no difference by sex [2, 4, 12]. However,
sex differences in the incidence rate of anal cancer are difficult
to interpret without also knowing the sexual orientation
among men.
Discrepant results for sex and MSM status across studies may
reflect variation in sexual risk behaviors among populations,
thus contributing to differences in the prevalence of anal
human papillomavirus (HPV). Prior studies have indicated
very high anal HPV prevalence, particularly for HIV-infected
MSM (prevalence ranging from 85% to 95%) [20–22] but also
for HIV-infected women (prevalence ranging from 76% to
90%) [23, 24], heterosexual men (prevalence of 60%) [20], and
injection drug users (prevalence of 46%) [22]. D’Souza et al
Figure 2. Anal cancer incidence rates by calendar era for human immunodeficiency virus infected men who have sex with men (MSM), other men, and
women, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), years 1996–2007. Vertical lines are 95% confidence intervals.
P values from the Poisson regression model compare rates by calendar era with 2000–2003 as reference. The global P value for comparison of rates
across eras is based on the likelihood ratio statistic.
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[11] reported that among MSM, a higher cumulative number
of reported unprotected anal receptive partners at study
baseline was associated with a higher incidence rate of anal
cancer.
We also found that among HIV-infected persons, anal cancer
incidence rates increased between 1996–1999 and 2000–2003,
followed by stable rates. This pattern was similar for MSM, other
men, and women and was independent of other factors, in-
cluding age, race/ethnicity, and baseline CD4. Many studies,
but not all [2, 4], have reported increases in anal cancer in-
cidence rates over time in HIV-infected persons [5, 8, 9,
11, 12, 19, 25–28]; however, these studies compared rates be-
tween the pre-ART and ART eras. Among previous studies that
evaluated trends over time during the ART era, some indicated
continued increasing rates [8, 25, 26], whereas others found
no increases during more recent years [10, 12]. However, of the
3 studies showing continued increases, 2 had a small sample
size and few events in the most recent era [25, 26], and the third
evaluated trends only through 2003 [8]. Similar to our results,
the large French Hospital Database study observed an increase
in anal cancer incidence rates for HIV-infected MSM, other
men, and women through 1998, but no significant change in
rates after 1999 [12].
Our finding of stabilizing rates in the ART era may mask
opposing pressures on anal cancer risk. On one hand, the im-
proved survival for HIV-infected individuals in the ART era
results in longer exposure to HPV infection, which may result
in increased risk of HPV-associated cancers [8, 12]. Crum-
Cianflone et al [26], for example, observed that anal cancer
was most common among HIV-infected patients with known
duration of HIV infection of $15 years. On the other hand,
anal cancer in HIV-infected patients may be related to im-
munosuppression [1, 11, 12, 29, 30], which was supported
here by the observed association of baseline CD4 and anal
cancer incidence rates. If true, then improvements in immune
function over time with the use of ART may result in de-
creased anal cancer risk.
Our study had limitations. First, we lacked data on several
factors, including HPV infection, sexual behavior, smoking,
and anal cancer screening, which would help further elucidate
differences between groups. Regarding anal cancer screening,
there might have been more vigilance for anal cancer among
HIV-infected MSM than among HIV-infected other men and
HIV-infected women, and among HIV-infected persons than
among HIV-uninfected persons. Such differences in screening
could have biased results in either direction, as screening could
result in diagnosis of both anal cancers and of precancerous
lesions. Treatment of the latter could result in decreased anal
cancer incidence, which might explain the observed plateau in
anal cancer rates. To the extent that screening practices differ
from cohorts included here from the United States and Canada,
results may have limited generalizability to other populations.
An additional limitation was the lack of information on
sexual orientation for HIV-uninfected individuals. Because
MSM, whether or not they are HIV-infected, may be at in-
creased risk for anal cancer [31], it is possible that confounding
by MSM status contributed to the increased anal cancer risk we
observed among HIV-infected MSM; however, few others have
compared risk directly between HIV-infected and HIV-
uninfected MSM to avoid this potential confounding [9, 11].
Also, among HIV-infected individuals, there may have been
misclassification of sexual orientation, resulting in some MSM
classified as other men. A further limitation was that anal
cancer was rare in the HIV-uninfected population, limiting
our statistical power and requiring us to use a single HIV-
uninfected comparison group (not stratified by calendar era).
Table 2. Adjusted Anal Cancer Incidence Rate Ratios Between HIV-Infected Individuals Compared With HIV-Uninfected Individuals and
With National US SEER Rates (Standardized Incidence Ratios), North American AIDS Cohort Collaboration on Research and Design
(NA-ACCORD), Years 1996–2007
Rate Ratio (95% CI)a,b Standardized Incidence Ratio (95% CI)c
Calendar Era MSM Other Men MSM Other Men Women
1996–1999 60.8 (28.3–130.3) 18.2 (3.9–85.0) 73.9 (44.5–110.7) 17.4 (2.1–48.6) 0 (0–0)d
2000–2003 100.8 (51.7–196.5) 27.3 (9.1–81.8) 115.6 (86.1–149.5) 24.8 (8.1–50.8) 41.5 (16.7–77.4)
2004–2007 78.8 (40.8–152.1) 31.9 (11.9–85.4) 78.7 (58.2–102.2) 20.3 (6.6–41.5) 24.7 (9.1–48.0)
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; MSM, men who have sex with men.
a Rate ratios for HIV-infected MSM and other men by calendar era compared with HIV-uninfected men (not stratified by era) from Poisson regression models
adjusted for race/ethnicity (imputed for unknown), age at entry into calendar era, and cohort. The rate ratio was undefined for women because there were no cases
in the reference group of HIV-uninfected women.
b The P values for the rate ratios comparing 1996–1999 vs 2000–2003 and 2000–2003 vs 2004–2007 were P 5 .06 and P 5 .22, respectively, for MSM; and
P 5 .63 and P 5 .79, respectively, for other men.
c Age (,30, 30–39, 40–49, and $50) and sex and race/ethnicity (white, black, other) standardized incidence ratios computed using national US SEER rates from
1996 through 2005; individuals with missing race were dropped in the SIR analysis.
d The SIR for women in 1996–1999 was 0 because the single female case diagnosed in 1996–1999 had missing race, and was therefore dropped in the SIR analysis.
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Furthermore, there were no cases among women in the HIV-
uninfected comparison group, precluding a direct comparison
of anal cancer incidence rates by HIV status among women.
Finally, neither the internal comparison group nor the external
SEER rates included Canadians, even though our analysis in-
cluded 3 HIV-infected Canadian cohorts.
Study strengths were evaluation of anal cancer rates for several
well-defined groups of HIV-infected individuals (ie, MSM,
other men, and women) and inclusion of an HIV-uninfected
comparison group. The similarity of our results using this
comparison group and the SEER rates as the comparison
demonstrates the robustness of our findings. An additional
strength was the very large sample size and the geographic and
demographic diversity represented by the contributing cohorts.
Our finding of high anal cancer incidence rates in HIV-
infected MSM, other men, and women suggests the need for
enhanced primary and secondary prevention efforts among
all HIV-infected persons, as opposed to a targeted approach.
The HPV vaccine has been shown to be highly effective for
prevention of anal cancer precursor lesions in women [32]
and was recently approved for prevention of anal cancer [33].
Furthermore, vaccination of boys [34] or high-risk groups,
such as MSM [35], can be highly cost effective. However, it
remains to be seen how efficacious the vaccine will be for HIV-
infected patients [36]. Anal dysplasia screening may also prove
to be a cost-effective approach to preventing cancer in HIV-
infected individuals [37, 38]. The New York State AIDS In-
stitute guidelines for anal cancer screening of HIV-infected
patients recommend annual digital rectal examinations for all
patients, and targeted anal cytology for MSM, for individuals
with a history of anogenital warts, and for women with a his-
tory of abnormal cervical or vulvar histology [39]. However,
further research is needed to determine if such an approach will
ultimately result in a decreased burden of anal cancer [40].
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b Other race/ethnicity category was predominantly Hispanic.
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